Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Extended half-life products for children with hemophilia B reduce both bleeding episodes and the need for infusions, ...

Different types of assays led to different results in measures of factor IX variant FIX-R338L, the authors found. A new field study could help clinicians better interpret laboratory measurements of ...

Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product. Switching patients with ...

Fidanacogene elaparvovec gene therapy reduced the annualized bleeding rate by 71% in patients with hemophilia B. Factor IX activity levels were sustained at 26.9% at 15 months post-treatment.

A five-year study suggests gene therapy may help reduce bleeding and infusions as a hemophilia B treatment option.

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...

Idelvion (coagulation factor IX [recombinant], albumin fusion protein) is a prescription drug used to treat and help prevent bleeding episodes in people with hemophilia B. Idelvion is given as an ...

“ Despite several major advances in treatment options for people with hemophilia B, including extended-release recombinant factor IX biologics and the availability of a new gene therapy, significant ...

The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to ...